State Street
BTAI icon

State Street’s BioXcel Therapeutics BTAI Stock Holding History

State Street’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$130K Hold
92,118
– – ﹤0.01% 3931
2026
Q1 		$123K Buy
92,118
+28,900
+46% +$47.6K ﹤0.01% 3991
2025
Q4 		$101K Buy
63,218
+10,500
+20% +$21.7K ﹤0.01% 4045
2025
Q3 		$135K Buy
+52,718
New +$166K ﹤0.01% 3995
2025
Q1 		– Sell
-4,822
Closed -$28.8K – 4288
2024
Q4 		$28.8K Hold
4,822
– – ﹤0.01% 4191
2024
Q3 		$47.1K Sell
4,822
-2,975
-38% -$40K ﹤0.01% 4112
2024
Q2 		$160K Sell
7,797
-21,260
-73% -$712K ﹤0.01% 3880
2024
Q1 		$1.31M Buy
29,057
+1,536
+6% +$73.3K ﹤0.01% 3400
2023
Q4 		$1.3M Buy
27,521
+1,905
+7% +$106K ﹤0.01% 3425
2023
Q3 		$1.04M Sell
25,616
-103,896
-80% -$10.5M ﹤0.01% 3522
2023
Q2 		$13.8M Buy
129,512
+19,469
+18% +$6.48M ﹤0.01% 2465
2023
Q1 		$32.9M Buy
110,043
+87,007
+378% +$37.2M ﹤0.01% 1911
2022
Q4 		$7.92M Sell
23,036
-69
-0.3% -$16.7K ﹤0.01% 2834
2022
Q3 		$4.37M Buy
23,105
+276
+1% +$64.1K ﹤0.01% 3132
2022
Q2 		$4.82M Sell
22,829
-64,718
-74% -$13.6M ﹤0.01% 3122
2022
Q1 		$29.3M Buy
87,547
+3,478
+4% +$1.01M ﹤0.01% 2125
2021
Q4 		$27.3M Buy
84,069
+1,032
+1% +$443K ﹤0.01% 2237
2021
Q3 		$40.3M Sell
83,037
-8,158
-9% -$3.59M ﹤0.01% 1969
2021
Q2 		$42.4M Buy
91,195
+11,451
+14% +$6.24M ﹤0.01% 1973
2021
Q1 		$55.1M Sell
79,744
-24,881
-24% -$20M ﹤0.01% 1672
2020
Q4 		$77.3M Buy
104,625
+23,759
+29% +$18.5M ﹤0.01% 1353
2020
Q3 		$56.1M Buy
80,866
+19,967
+33% +$15M ﹤0.01% 1372
2020
Q2 		$51.7M Buy
60,899
+53,012
+672% +$34.6M ﹤0.01% 1445
2020
Q1 		$2.82M Buy
7,887
+1,640
+26% +$589K ﹤0.01% 2905
2019
Q4 		$1.46M Buy
6,247
+946
+18% +$95.1K ﹤0.01% 3339
2019
Q3 		$597K Buy
5,301
+1,292
+32% +$204K ﹤0.01% 3478
2019
Q2 		$526K Buy
+4,009
New +$679K ﹤0.01% 3504

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street's BTAI Position: Q2 2026 in Review

State Street held its BioXcel Therapeutics (BTAI) position steady in Q2 2026 at 92,118 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #3931.

State Street first reported a position in BTAI in Q2 2019 and has held it in 27 quarters since. The position peaked at $77.3M in Q4 2020. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • State Street held 92,118 shares of BioXcel Therapeutics worth $130K as of Q2 2026.
  • State Street left its BioXcel Therapeutics share count unchanged in Q2 2026.
  • BioXcel Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3931 holding.
  • State Street first reported a position in BioXcel Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • State Street's BioXcel Therapeutics position peaked at $77.3M in Q4 2020.
  • 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.